Get the Stockscreener App
23.20
5.69%
-1.40
After Hours:
23.21
0.01
+0.04%
Ascentage Pharma Group International Adr stock is traded at $23.20, with a volume of 1,909.
It is down -5.69% in the last 24 hours and down -18.25% over the past month.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
See More
Previous Close:
$24.60
Open:
$23.832
24h Volume:
1,909
Relative Volume:
0.44
Market Cap:
$2.16B
Revenue:
$136.33M
Net Income/Loss:
$-56.34M
P/E Ratio:
-30.92
EPS:
-0.7504
Net Cash Flow:
$-18.87M
1W Performance:
-4.09%
1M Performance:
-18.25%
6M Performance:
-42.29%
1Y Performance:
+29.97%
1-Day Range:
$23.20
$23.99
1-Week Range:
$23.20
$24.60
52-Week Range:
$17.09
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Name
Ascentage Pharma Group International Adr
Sector
Industry
Phone
-
Address
-
Compare AAPG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
23.20 | 2.29B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Dec-04-25 | Initiated | Oppenheimer | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-10-25 | Initiated | BTIG Research | Buy |
| Nov-05-25 | Initiated | Piper Sandler | Overweight |
| Mar-27-25 | Initiated | JP Morgan | Overweight |
View All
Ascentage Pharma Group International Adr Stock (AAPG) Latest News
Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target - Finviz
Ascentage Pharma to Present at Guggenheim Biotech Summit as Late-Stage Oncology Pipeline Expands - TipRanks
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Ascentage Pharma Wins China IND Clearance for Next-Gen BTK Degrader APG-3288 - TipRanks
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - GlobeNewswire Inc.
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Sahm
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpTime to Buy? - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownWhat's Next? - MarketBeat
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World
Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial - TipRanks
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 - Sahm
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.50 Average Price Target from Brokerages - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.5%Should You Sell? - MarketBeat
Ascentage Pharma to Present at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma to Engage Investors at December 2025 Conferences - MSN
Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025 - The Globe and Mail
Ascentage Pharma showcases promising data for olverembatinib at ASH 2025 - MSN
Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025 - TipRanks
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LSX:A40ZYR - TradingView
ETFs Investing in Ascentage Pharma Group International Unsponsored ADR Stocks - TradingView — Track All Markets
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LS:A40ZYR - TradingView
Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast - TipRanks
Ascentage Pharma Announces New RSU and Share Option Grants - TipRanks
Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail
Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Now Covered by Analysts at Truist Financial - Defense World
Ascentage Pharma Group International Adr Stock (AAPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):